NASDAQ:CLGN CollPlant Biotechnologies (CLGN) Stock Price, News & Analysis $4.13 +0.22 (+5.63%) Closing price 10/14/2026 04:00 PM EasternExtended Trading$3.99 -0.14 (-3.39%) As of 07:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsNews and TrendsOptions ChainOwnershipSEC Filings About CollPlant Biotechnologies Stock (NASDAQ:CLGN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CLGN alerts:Sign Up Key Stats Today's Range$3.82▼$4.1350-Day Range$2.90▼$4.5652-Week Range$2.64▼$26.80Volume39,702 shsAverage Volume73,202 shsMarket Capitalization$7.81 millionP/E RatioN/ADividend YieldN/APrice Target$120.00Consensus RatingReduce Company Overview CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) is an Israel-based biotechnology company developing regenerative medicine products and tissue-engineering technologies. The company’s platform uses genetically engineered tobacco plants to produce recombinant human collagen (rhCollagen), a purified collagen material designed to support the repair, replacement, and regeneration of human tissue. CollPlant develops rhCollagen-based products for applications including 3D bioprinting, tissue engineering, and advanced wound care. Its technologies are intended for use in bioinks, scaffolds, and other medical products, with research focused particularly on soft-tissue reconstruction and implantable regenerative solutions. The company has also pursued collaborations with medical technology and bioprinting companies to develop next-generation human tissue and organ-replacement products. CollPlant traces its origins to 2004 and is headquartered in Rehovot, Israel. Its business is internationally oriented, with research, development, and commercial collaboration activities involving partners and potential customers in multiple global markets. The company is led by Chief Executive Officer Yehiel Tal.AI Generated. May Contain Errors. Read More CollPlant Biotechnologies Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreCLGN MarketRank™: 2.670872765505 of 5 starsCollPlant Biotechnologies scored higher than 53% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingReduce Consensus RatingCollPlant Biotechnologies has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialCollPlant Biotechnologies has a consensus price target of $120.00, representing about 2,805.6% upside from its current price of $4.13.Amount of Analyst CoverageCollPlant Biotechnologies has only been the subject of 1 research reports in the past 90 days.Read more about CollPlant Biotechnologies' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of CollPlant Biotechnologies is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CollPlant Biotechnologies is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCollPlant Biotechnologies has a P/B Ratio of 0.87. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about CollPlant Biotechnologies' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.47% of the float of CollPlant Biotechnologies has been sold short.Short Interest Ratio / Days to CoverCollPlant Biotechnologies has a short interest ratio ("days to cover") of 0.54, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CollPlant Biotechnologies has recently decreased by 19.17%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCollPlant Biotechnologies does not currently pay a dividend.Dividend GrowthCollPlant Biotechnologies does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment0.91 News SentimentCollPlant Biotechnologies has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for CollPlant Biotechnologies this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for CLGN on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows2 people have added CollPlant Biotechnologies to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.6 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CollPlant Biotechnologies insiders have not sold or bought any company stock.Percentage Held by Insiders9.60% of the stock of CollPlant Biotechnologies is held by insiders.Percentage Held by Institutions21.69% of the stock of CollPlant Biotechnologies is held by institutions.Read more about CollPlant Biotechnologies' insider trading history. Receive CLGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CollPlant Biotechnologies and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CLGN Stock News HeadlinesCOLLPLANT ANNOUNCES A $3.7 MILLION PRIVATE PLACEMENTOctober 9, 2026 | prnewswire.comLightSolver Files U.S. Provisional Patent Application Expanding its Photonic Computing Platform to Advanced Scientific and Engineering SimulationsOctober 6, 2026 | prnewswire.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.October 15 at 1:00 AM | Chaikin Analytics (Ad)CollPlant Biotechnologies Q2 Net Loss NarrowsOctober 1, 2026 | rttnews.comCOLLPLANT REPORTS 2026 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATESeptember 30, 2026 | prnewswire.comLightSolver, a CollPlant Company, and HLRS Joint Research Demonstrated Photonic Computing Can significantly Accelerate Fundamental HPC WorkloadsSeptember 24, 2026 | prnewswire.comCollPlant Regains Nasdaq Minimum Bid Price Compliance; Stock UpSeptember 22, 2026 | rttnews.comCollPlant Regains Compliance with Nasdaq Minimum Bid Price RequirementSeptember 22, 2026 | prnewswire.comSee More Headlines CLGN Stock Analysis - Frequently Asked Questions How have CLGN shares performed this year? CollPlant Biotechnologies' stock was trading at $14.00 on January 1st, 2026. Since then, CLGN stock has decreased by 70.5% and is now trading at $4.13. How were CollPlant Biotechnologies' earnings last quarter? CollPlant Biotechnologies Ltd. Sponsored ADR (NASDAQ:CLGN) issued its earnings results on Wednesday, September, 30th. The company reported ($1.89) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.45) by $0.56. The business had revenue of $0.11 million for the quarter, compared to analysts' expectations of $0.48 million. CollPlant Biotechnologies had a negative trailing twelve-month return on equity of 298.21% and a negative net margin of 678.37%. When did CollPlant Biotechnologies' stock split? CollPlant Biotechnologies shares reverse split on the morning of Friday, September 4th 2026.A 1-10 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 3rd 2026. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did CollPlant Biotechnologies IPO? CollPlant Biotechnologies (CLGN) raised $22 million in an IPO on Friday, December 9th 2016. The company issued 3,500,000 shares at $6.23 per share. Ladenburg Thalmann served as the underwriter for the IPO and Roth Capital Partners was co-manager. How do I buy shares of CollPlant Biotechnologies? Shares of CLGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CollPlant Biotechnologies own? Based on aggregate information from My MarketBeat watchlists, some other companies that CollPlant Biotechnologies investors own include NVIDIA (NVDA), Palantir Technologies (PLTR), Advanced Micro Devices (AMD), Digital Turbine (APPS), Iovance Biotherapeutics (IOVA), SoFi Technologies (SOFI) and Tesla (TSLA). Company Calendar Last Earnings9/30/2026Today10/14/2026Next Earnings (Estimated)12/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (10m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 CLGN's financial health is in the Red zone, according to TradeSmith. CLGN has been in this zone for over 10 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CLGN CIK1631487 Webwww.collplant.com Phone972732325600Fax972-73-232-5602Employees39Year Founded1981Price Target and Rating Average Price Target for CollPlant Biotechnologies$120.00 High Price Target$120.00 Low Price Target$120.00 Potential Upside/Downside+2,805.6%Consensus RatingReduce Rating Score (0-4)1.50 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($13.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$11.49 million Net Margins-678.37% Pretax Margin-490.32% Return on Equity-298.21% Return on Assets-167.83% Debt Debt-to-Equity RatioN/A Current Ratio1.57 Quick Ratio1.35 Sales & Book Value Annual Sales$2.37 million Price / Sales3.29 Cash FlowN/A Price / Cash FlowN/A Book Value$4.76 per share Price / Book0.87Miscellaneous Outstanding Shares1,890,000Free Float1,709,000Market Cap$7.81 million OptionableOptionable Beta1.77 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:CLGN) was last updated on 10/14/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CollPlant Biotechnologies Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share CollPlant Biotechnologies With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CLGN Stock Alerts